<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320311426025</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320311426025</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Influence of ramiprilat and losartan on ischemia reperfusion injury in rat hearts</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Safari</surname><given-names>Fatemeh</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311426025">1</xref>
<xref ref-type="aff" rid="aff2-1470320311426025">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Hajizadeh</surname><given-names>Sohrab</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311426025">1</xref>
</contrib> <contrib contrib-type="author">
<name><surname>Shekarforoush</surname><given-names>Shahnaz</given-names></name>
<xref ref-type="aff" rid="aff3-1470320311426025">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bayat</surname><given-names>Gholamreza</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311426025">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Foadoddini</surname><given-names>Mohsen</given-names></name>
<xref ref-type="aff" rid="aff4-1470320311426025">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Khoshbaten</surname><given-names>Ali</given-names></name>
<xref ref-type="aff" rid="aff5-1470320311426025">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-1470320311426025"><label>1</label>Department of Physiology, Tarbiat Modares University, Tehran, Iran</aff>
<aff id="aff2-1470320311426025"><label>2</label>Deptartment of Physiology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</aff>
<aff id="aff3-1470320311426025"><label>3</label>Islamic Azad University, Arsanjan Branch, Fars, Iran</aff>
<aff id="aff4-1470320311426025"><label>4</label>Department of Physiology and Pharmacology, Birjand University of Medical Sciences, Birjand, Iran</aff>
<aff id="aff5-1470320311426025"><label>5</label>Exercise Physiology Research Center, Baqiatallah University of Medical Sciences, Tehran, Iran</aff>
<author-notes>
<corresp id="corresp1-1470320311426025">Sohrab Hajizadeh, Department of Physiology, Tarbiat Modares University, Tehran, Iran. Email: <email>fa.cardio@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>13</volume>
<issue>1</issue>
<fpage>29</fpage>
<lpage>35</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><italic>Hypothesis/introduction</italic>: Our aim was to investigate whether a non-hypotensive dose of ramiprilat and losartan has myocardial protective effects during myocardial ischemia/reperfusion in vivo.</p>
<p><italic>Materials and methods</italic>: Three groups of rats were given 10 mg/kg per day of losartan for one (L-1W), four (L-4W) or 10 (L-10W) weeks. Another three groups were given 50 µg/kg per day of ramiprilat for one (R-1W), four (R-4W) or 10 (R-10W) weeks. The animals underwent 30 min of left anterior descending artery occlusion and subsequent reperfusion for 120 min.</p>
<p><italic>Results</italic>: Myocardial infarct size (IS) was reduced in R-1W (28.4 ± 6.3%, <italic>p</italic> &lt; 0.001), R-4W (27.8 ± 7.4, <italic>p</italic> &lt; 0.001), L-4W (31.8 ± 6%, <italic>p</italic> &lt; 0.05) and L-10W (25.3 ± 5.7, <italic>p</italic> &lt; 0.001) groups compared with a saline group (48.3 ± 7.8%). A significant reduction in the number of ventricular ectopic beats (VEBs) was noted in groups R-1W (209 ± 41, <italic>p</italic> &lt; 0.01), R-4W (176 ± 39, <italic>p</italic> &lt; 0.01), L-4W (215 ± 52, <italic>p</italic> &lt; 0.05) and L-10W (191 ± 61, <italic>p</italic> &lt; 0.01 <italic>vs</italic>. saline 329 ± 48). The incidence of irreversible ventricular fibrillation (VF) and mortality were decreased significantly only in L-10W group.</p>
<p>There were no significant decreases in episodes of VT, the incidence of irreversible VF and mortality in all of the groups treated with ramiprilat.</p>
<p><italic>Conclusion</italic>: These data indicate that losartan and ramiprilat protect the heart against ischemia/reperfusion injury independently of their hemodynamic effects but in a time-dependent manner.</p>
</abstract>
<kwd-group>
<kwd>Arrhythmia</kwd>
<kwd>infarct size</kwd>
<kwd>losartan</kwd>
<kwd>ramiprilat</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1470320311426025" sec-type="intro">
<title>Introduction</title>
<p>The renin–angiotensin system (RAS) is an important factor with implication in the pathogenesis of myocardial ischemia reperfusion injury. As a result, pharmacologic blockade of this system has been an attractive strategy for cardioprotection against ischemia reperfusion injury.<sup><xref ref-type="bibr" rid="bibr1-1470320311426025">1</xref></sup></p>
<p>Ramipril is a weak but long acting angiotensin converting enzyme (ACE) inhibitor prodrug and is converted in the liver into the more active metabolite ramiprilat. Most experiments with this ACE inhibitor (ACEi)<sup><xref ref-type="bibr" rid="bibr2-1470320311426025">2</xref>-<xref ref-type="bibr" rid="bibr9-1470320311426025">9</xref></sup> and with angiotensin type 1 (AT<sub>1</sub>) receptor blocker (ARB) losartan<sup><xref ref-type="bibr" rid="bibr10-1470320311426025">10</xref>-<xref ref-type="bibr" rid="bibr16-1470320311426025">16</xref></sup> have shown that these agents are able to protect the myocardium against ischemia reperfusion injury by reduction of infarct size and ventricular arrhythmias.</p>
<p>In contrast, there are reports that have shown no significant beneficial effects for these drugs on infarct size and arrhythmias.<sup><xref ref-type="bibr" rid="bibr2-1470320311426025">2</xref>,<xref ref-type="bibr" rid="bibr3-1470320311426025">3</xref>,<xref ref-type="bibr" rid="bibr17-1470320311426025">17</xref>-<xref ref-type="bibr" rid="bibr19-1470320311426025">19</xref></sup> Several clinical trials have also established a therapeutic benefit for ramipril<sup><xref ref-type="bibr" rid="bibr20-1470320311426025">20</xref>-<xref ref-type="bibr" rid="bibr22-1470320311426025">22</xref></sup> and losartan<sup><xref ref-type="bibr" rid="bibr23-1470320311426025">23</xref>,<xref ref-type="bibr" rid="bibr24-1470320311426025">24</xref></sup> in decreasing mortality due to cardiovascular events, but the results are inconsistent. There are reports which indicate that some of the protective effects of ACEi and ARBs may occur independently of their ability to decrease arterial blood pressure.<sup><xref ref-type="bibr" rid="bibr25-1470320311426025">25</xref>,<xref ref-type="bibr" rid="bibr26-1470320311426025">26</xref></sup> On the other hand, in most experimental studies, ACEi or ARBs were given as an acute pretreatment prior to induction of myocardial infarction.<sup><xref ref-type="bibr" rid="bibr3-1470320311426025">3</xref>,<xref ref-type="bibr" rid="bibr5-1470320311426025">5</xref>,<xref ref-type="bibr" rid="bibr8-1470320311426025">8</xref>,<xref ref-type="bibr" rid="bibr9-1470320311426025">9</xref>,<xref ref-type="bibr" rid="bibr15-1470320311426025">15</xref></sup> Both ACEi and ARBs are usually given chronically to patients in clinical practice and it is important to know the effect of different durations of pretreatment with these drugs on myocardial ischemia reperfusion injury. The present experiments were designed to further investigate the effects of different durations of pretreatment with non-hypotensive doses of an ACEi, ramiprilat, and a AT1 receptor blocker, losartan, on myocardial infarct size and incidence of arrhythmias in a rat model of myocardial ischemia reperfusion injury.</p>
</sec>
<sec id="section2-1470320311426025" sec-type="materials|methods">
<title>Material and methods</title>
<sec id="section3-1470320311426025">
<title>Experimental groups</title>
<p>Animals were housed in a room controlled for temperature and light (12 h light/dark cycle). All experimental procedures were performed in accordance with the approval of the Ethics Committee on Animal Experiments of the Tarbiat Modares University. Male Wistar rats with an average body weight of 250–300 g were randomly assigned to seven groups: three groups were given 10 mg/kg per day of losartan (Daru Pakhsh) for one week (L-1W) (<italic>n</italic> = 22), four weeks (L-4W) (<italic>n</italic> = 22) or 10 weeks (L-10W) (<italic>n</italic> = 15). Another three groups were given 50 µg/kg per day of ramiprilat (Sanofi-Aventis) for one week (R-1W) (<italic>n</italic> = 23), four weeks (R-4W) (<italic>n</italic> = 18) or 10 weeks (R-10W) (<italic>n</italic> = 18). The seventh group was given saline solution and served as control (<italic>n</italic> = 16). All drugs were dissolved in saline and administered orally using a feeding needle in a 2 ml volume as a single dose. The data from a preliminary experiment designed to record blood pressure showed that one to two weeks’ administration of 50 µg/kg per day of ramiprilat and 10 mg/kg per day of losartan did not induce hypotension in rats (data not shown).</p>
</sec>
<sec id="section4-1470320311426025">
<title>Ischemia reperfusion protocols</title>
<p>A rat model of myocardial ischemia reperfusion was used as previously described.<sup><xref ref-type="bibr" rid="bibr27-1470320311426025">27</xref></sup> Anesthesia was induced by using sodium pentobarbital (50 mg/kg, i.p.). After a midline incision, the trachea was intubated and ventilated artificially with room air at a tidal volume of 1 ml/100 g and a frequency of 70–80 inflation/min. Body temperature was monitored with a rectal probe and maintained at 37°C using a heating pad. The tail vein was cannulated for injection of Evans blue. Lead II of electrocardiogram (ECG) was recorded using skin needle electrodes. Arterial blood pressure was monitored from the left carotid artery by a blood pressure transducer. The chest was opened by a left thoracotomy in the fourth intercostals space. The pericardium was incised and the heart was exposed. A 5/0 silk thread was passed below the left anterior descending (LAD) branch of the coronary artery and was occluded for 30 min by lifting the thread through a piece of polyethylene tube. Development of a pale color in the distal myocardium, S-T elevation on ECG and reducing of the blood pressure confirmed successful coronary occlusion. After 30 min of ischemia, loosening the silk thread allowed heart reperfusion for 120 min. Restoration of bright red color of the left ventricle verified the reperfusion.</p>
</sec>
<sec id="section5-1470320311426025">
<title>Evaluation of ischemia-induced arrhythmias</title>
<p>Arrhythmias were assessed according to the diagnostic criteria in the Lambeth conventions:<sup><xref ref-type="bibr" rid="bibr28-1470320311426025">28</xref></sup> ventricular ectopic beats (VEBs) are discrete and identifiable premature QRS complex ventricular tachycardia (VT) is defined as a run of four or more consecutive VEBs. Ventricular fibrillation (VF) is defined as a signal where QRS complexes could not easily be distinguished from each other and heart rate could no longer be measured. The number of VEBs, the episodes of VT and the incidence of VF were determined. VEBs included bigeminy and salvos too.</p>
</sec>
<sec id="section6-1470320311426025">
<title>Infarct size measurement</title>
<p>Delineation of infarct size was performed as described previously.<sup><xref ref-type="bibr" rid="bibr27-1470320311426025">27</xref></sup> After 120 min of reperfusion, the LAD was re-ligated and 1 ml of Evans blue solution (1%) was injected into the tail vein so that the non-ischemic portion of the heart stained blue. The area that remained unstained by Evans blue was pale and defined as area at risk (AAR). The heart was then excised rapidly and put in a matrix and frozen at -20 (12 h) for evaluation of the infarct size. Frozen heart was cut parallel to the atrioventricular groove into 2 mm thick sections. Slices were incubated in 1% triphenyl tetrazolium chloride (TTC) solution in pH 7.4 phosphate buffer for 20 min at 37°C. TTC stains viable tissue a red color while infracted tissue looks tan. Slices were incubated in a 10% formalin solution for 24 h to enhance the contrast. An image was obtained (CanonScan Lid 25) from both sides of each slice and all calculations from one heart (using Image Tool Software) were averaged into one value for statistical analysis. Infarct size, as the white color area, was expressed as a percentage of AAR.</p>
</sec>
<sec id="section7-1470320311426025">
<title>Statistical analysis</title>
<p>The data were expressed as means ± SD. Infarct size, the number of VEBs and hemodynamic values were analyzed by the Kruskal–Wallis test with Dunn’s post-test for multiple comparison. The incidences of VF were analyzed by using Fisher’s exact test. Hemodynamic values within the same group were analyzed by repeated measures analysis of variance. Outcomes were assessed by Kaplan–Meier survival analysis and log-rank test statistics. Differences were considered statistically significant when <italic>p</italic> &lt; 0.05.</p>
</sec>
</sec>
<sec id="section8-1470320311426025" sec-type="results">
<title>Results</title>
<sec id="section9-1470320311426025">
<title>Hemodynamic parameters</title>
<p><xref ref-type="table" rid="table1-1470320311426025">Table 1</xref> shows the effect of pretreatment with ramiprilat and losartan on blood pressure and heart rate before LAD occlusion (baseline), at the end of ischemia and at the end of reperfusion. In all groups, shortly after LAD occlusion blood pressure decreased significantly and returned to pre-occlusion values after reperfusion. In all groups, heart rate was stable throughout the experiments. There were no significant differences in blood pressure and heart rate among the seven groups at baseline, during ischemia or during reperfusion.</p>
<table-wrap id="table1-1470320311426025" position="float">
<label>Table 1.</label>
<caption>
<p>Mean blood pressure (MBP) (mm Hg) and heart rate (HR) (beats/min) obtained before occlusion of the LAD artery and at the end of ischemia and reperfusion in rats treated with losartan for one week (L-1W), four weeks (L-4W) or 10 weeks (L-10W) and ramiprilat for one week (R-1W), four weeks (R-4W) or 10 weeks (R-10W)</p>
</caption>
<graphic alternate-form-of="table1-1470320311426025" xlink:href="10.1177_1470320311426025-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left" colspan="2">Baseline</th>
<th align="left" colspan="2">Ischemia</th>
<th align="left" colspan="2">Reperfusion</th>
</tr>
<tr>
<th/>
<th align="left">MBH</th>
<th align="left">HR</th>
<th align="left">MBH</th>
<th align="left">HR</th>
<th align="left">MBH</th>
<th align="left">HR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saline</td>
<td>115±7</td>
<td>358±19</td>
<td>85±6<xref ref-type="table-fn" rid="table-fn1-1470320311426025">**</xref></td>
<td>366±14</td>
<td>107±8</td>
<td>346±16</td>
</tr>
<tr>
<td>L-1W</td>
<td>117±6</td>
<td>343±17</td>
<td>82±9<xref ref-type="table-fn" rid="table-fn1-1470320311426025">*</xref></td>
<td>374±12</td>
<td>111±7</td>
<td>350±16</td>
</tr>
<tr>
<td>L-4W</td>
<td>114±7</td>
<td>364±15</td>
<td>90±7<xref ref-type="table-fn" rid="table-fn1-1470320311426025">*</xref></td>
<td>375±21</td>
<td>110±9</td>
<td>356±19</td>
</tr>
<tr>
<td>L-10W</td>
<td>109±8</td>
<td>356±16</td>
<td>82±5<xref ref-type="table-fn" rid="table-fn1-1470320311426025">*</xref></td>
<td>365±17</td>
<td>100±6</td>
<td>348±14</td>
</tr>
<tr>
<td>R-1W</td>
<td>100±10</td>
<td>342±26</td>
<td>77±8<xref ref-type="table-fn" rid="table-fn1-1470320311426025">**</xref></td>
<td>371±19</td>
<td>95±9</td>
<td>357±21</td>
</tr>
<tr>
<td>R-4W</td>
<td>108±7</td>
<td>368±13</td>
<td>84±8<xref ref-type="table-fn" rid="table-fn1-1470320311426025">**</xref></td>
<td>376±13</td>
<td>113±8</td>
<td>360±16</td>
</tr>
<tr>
<td>R-10W</td>
<td>112±6</td>
<td>361±15</td>
<td>88±11<xref ref-type="table-fn" rid="table-fn1-1470320311426025">*</xref></td>
<td>377±17</td>
<td>104±7</td>
<td>358±25</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1470320311426025">
<p>Data are expressed as mean ± SD. * <italic>p</italic> &lt; 0.05 and **<italic>p</italic> &lt; 0.01 compared with baseline values within the same group.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section10-1470320311426025">
<title>Myocardial infarct size</title>
<p><xref ref-type="fig" rid="fig1-1470320311426025">Figure 1</xref> shows the effect of different durations of pretreatment with ramiprilat and losartan on myocardial infarct size. In all experimental groups, the size of AAR did not differ between the groups indicating equal position of LAD occlusion (<xref ref-type="fig" rid="fig1-1470320311426025">Figure 1A</xref>). Myocardial infarct size was unchanged after one week of pretreatment with losartan (42.1 ± 6% <italic>vs</italic>. saline 48.3 ± 7.8%), but was significantly reduced by four and 10 weeks of pretreatment (31.8 ± 6%, <italic>p</italic> &lt; 0.05 and 25.3 ± 5.7, <italic>p</italic> &lt; 0.001 <italic>vs</italic>. saline 48.3 ± 7.8%, respectively). Prolonged administration of losartan by 10 weeks (L-10W) showed greater reduction in infarct size compared with L-1W (<italic>p</italic> &lt; 0.01).</p>
<fig id="fig1-1470320311426025" position="float">
<label>Figure 1.</label>
<caption>
<p>Infarct size assessed following myocardial ischemia reperfusion. Rats were treated with saline, losartan or ramiprilat. Area at risk (AAR) expressed as percent of left ventricle area (LV), and myocardial infarct size as a percentage of AAR. Values are expressed as mean ± SD.</p>
<p>*<italic>p</italic> &lt; 0.05, ***<italic>p</italic> &lt; 0.001 <italic>vs</italic>. saline, <sup>&amp;</sup><italic>p</italic> &lt; 0.05, <sup>$$</sup><italic>p</italic> &lt; 0.01 <italic>vs</italic>. L-1W group. Rats treated with: L-1W: losartan for one week, L-4W: losartan for four weeks, L-10W: losartan for 10 weeks, R-1W: ramiprilat for one week, R-4W: ramiprilat for four weeks, R-10W: ramiprilat for 10 weeks.</p>
</caption>
<graphic xlink:href="10.1177_1470320311426025-fig1.tif"/>
</fig>
<p>Infarct size was significantly reduced one and four weeks after pretreatment with ramiprilat (28.4 ± 6.3%, <italic>p</italic> &lt; 0.001 and 27.8 ± 7.4, <italic>p</italic> &lt; 0.001 <italic>vs</italic>. saline 48.3 ± 7.8%, respectively). In the group treated with ramiprilat for 10 weeks, infarct size was reduced but it was not statistically significant (<xref ref-type="fig" rid="fig1-1470320311426025">Figure 1B</xref>). Interestingly, infarct size showed a marked reduction when R-1W group was compared with L-1W animals (<italic>p</italic> &lt; 0.05).</p>
</sec>
<sec id="section11-1470320311426025">
<title>Evaluation of arrhythmia and survival</title>
<p>After LAD occlusion, all animals exhibited cardiac arrhythmia. The arrhythmias were evaluated as VEBs, episodes of VT and the incidence of VF. The results of pretreatment with losartan and ramiprilat on ischemia-induced arrhythmias are illustrated in <xref ref-type="fig" rid="fig2-1470320311426025">Figure 2</xref>.</p>
<fig id="fig2-1470320311426025" position="float">
<label>Figure 2.</label>
<caption>
<p>The number of ventricular ectopic beats (VEBs), episodes of ventricular tachycardia (VT) and incidence of ventricular fibrillation (VF) during ischemia in rats treated with saline, losartan or ramiprilat. All data are expressed as mean ± S.D.</p>
<p>*<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01 <italic>vs</italic>. saline, <sup>&amp;,#</sup><italic>p</italic> &lt; 0.05 <italic>vs</italic>. L-1W and R-10W. Rats treated with: L-1W: losartan for one week, L-4W: losartan for four weeks, L-10W: losartan for 10 weeks, R-1W: ramiprilat for one week, R-4W: ramiprilat for four weeks, R-10W: ramiprilat for 10 weeks.</p>
</caption>
<graphic xlink:href="10.1177_1470320311426025-fig2.tif"/>
</fig>
<p>All of these sever arrhythmias in the group treated with losartan for one week did not significantly change but in the group treated for four weeks, the total number of VEBs and the episodes of VT were decreased significantly (VEBs: 215 ± 52, <italic>p</italic> &lt; 0.05 <italic>vs</italic>. saline 329 ± 48; VT: 21 ± 6, <italic>p</italic> &lt; 0.05 <italic>vs</italic>. saline 33 ± 8 ). After prolonged (10 weeks) pretreatment with losartan, the number of VEBs (191 ± 61, <italic>p</italic> &lt; 0.01 <italic>vs</italic>. saline 329 ± 48), the episodes of VT (18 ± 5, <italic>p</italic> &lt; 0.01 <italic>vs</italic>. saline 33 ± 8) and the incidence of irreversible VF (9%, <italic>p</italic> &lt; 0.05 <italic>vs</italic>. saline 30%) were decreased significantly.</p>
<p>One and four weeks of pretreatment with ramiprilat significantly reduced the number of VEBs in R-1W and R-4W (209 ± 41, 176 ± 39, <italic>p</italic> &lt; 0.01 <italic>vs</italic>. saline respectively) groups but prolonged (10 weeks) pretreatment did not change the number of VEBs significantly. There were no significant decreases in episodes of VT and the incidence of VF in all of the groups that were treated with ramiprilat.</p>
<p>During the pretreatment period one rat from R-4W and two rats from L-4W groups died on days 6, 17 and 22 respectively. In our experimental model most of the mortalities occurred 10 to 15 minutes after LAD occlusion. Mortality was rarely seen during the reperfusion period. Further, in most of the animals mortality was accompanied with the occurrence of irreversible VF but the LAD occlusion-induced sever hypotension was another cause of mortality in some animals. In groups L-1W: seven of 22, L-4W: five of 22, R-1W: eight of 23, R-4W: four of 23 and R-10W: six of 18 rats died during the experiment. In most of the treated rats survival was higher than in saline (five of 16 rats) but the difference was not significant. However, in L-10W group only two of 15 rats died during the experiment. Comparison of the survival curves by log-rank test indicated a significant effect of the pretreatment with losartan for 10 weeks (<italic>p</italic> &lt; 0.05) (<xref ref-type="fig" rid="fig3-1470320311426025">Figure 3</xref>).</p>
<fig id="fig3-1470320311426025" position="float">
<label>Figure 3.</label>
<caption>
<p>Kaplan–Meier survival curve demonstrating a decrease in rate of death in L-10W group as compared with saline group. Rats treated with: L-1W: losartan for one week, L-4W: losartan for four weeks, L-10W: losartan for 10 weeks, R-1W: ramiprilat for one week, R-4W: ramiprilat for four weeks, R-10W: ramiprilat for 10 weeks.</p>
</caption>
<graphic xlink:href="10.1177_1470320311426025-fig3.tif"/>
</fig>
</sec>
</sec>
<sec id="section12-1470320311426025" sec-type="discussion">
<title>Discussion</title>
<p>In the present study the effects of different durations of pretreatment with non-hypotensive doses of an ACEi, ramiprilat, and an AT1 receptor blocker, losartan, were evaluated in a rat model of ischemia reperfusion injury.</p>
<p>The main findings of this study were: first, one week of pretreatment with losartan did not have a significant protective effect against myocardial ischemia reperfusion injury but four and 10 weeks of pretreatment significantly decreased myocardial infarct size and ischemia-induced arrhythmia. Second, the infarct size and total number of VPBs markedly reduced in rats treated with ramiprilat for one and four weeks. Prolongation of treatment from one to four weeks did not have any further cardioprotective effect but the cardioprotective effect was lost by increasing the duration of pretreatment to 10 weeks. The important outcome of the study is that it provides new evidence for the cardioprotective effect of ramiprilat and losartan even at non-hypotensive dosage. Furthermore, our findings suggest that the cardioprotective effect of ramiprilat and losartan is time dependent.</p>
<p>It is possible that the results of the current study were influenced by the dose of drugs. A dose which was effective but did not change blood pressure or heart rate significantly was used in order to exclude the influence of systemic hemodynamic alterations. The data from a pilot study designed to record basic hemodynamic parameters had shown that one to two weeks’ administration of 50 µg/kg per day of ramiprilat and 10 mg/kg per day of losartan did not induce hypotension in rats, as reported previously using the same dose.<sup><xref ref-type="bibr" rid="bibr5-1470320311426025">5</xref>,<xref ref-type="bibr" rid="bibr11-1470320311426025">11</xref>,<xref ref-type="bibr" rid="bibr12-1470320311426025">12</xref></sup></p>
<p>Moreover in the present study the AARs were similar in all the groups and the infarct size values were similar to those reported by others in rats subjected to 30 min of coronary occlusion followed by 120 min of reperfusion.<sup><xref ref-type="bibr" rid="bibr18-1470320311426025">18</xref>,<xref ref-type="bibr" rid="bibr27-1470320311426025">27</xref></sup> Heart rate and blood pressure were the same in these seven groups during 30 min of ischemia and 120 min of reperfusion. Coronary artery occlusion caused a marked drop in arterial blood pressure and administration of ramiprilat or losartan did not induce any further lowering of blood pressure, suggesting that losartan and ramiprilat reduced infarct size independently of hypotensive or chronotropic effects (<xref ref-type="table" rid="table1-1470320311426025">Table 1</xref>).</p>
<p>In the present study ramiprilat reduced infarct size significantly as previously reported in mice,<sup><xref ref-type="bibr" rid="bibr8-1470320311426025">8</xref></sup> rats,<sup><xref ref-type="bibr" rid="bibr9-1470320311426025">9</xref></sup> pigs<sup><xref ref-type="bibr" rid="bibr5-1470320311426025">5</xref></sup> and rabbits,<sup><xref ref-type="bibr" rid="bibr3-1470320311426025">3</xref></sup> although in all of these reports ramiprilat was administered as a single dose (50 µg/kg) prior to LAD occlusion or immediately before reperfusion. The effect of different time courses of pretreatment with ramiprilat on myocardial infarct size and ischemia-induce arrhythmia has not yet been investigated and as far as we understand, this finding is the first report in this issue. On the contrary, in a report by Black et al. administration of the same and lower doses of ramiprilat (50 µg/kg, 40 ng/kg) prior to or during ischemia did not reduce infarct size, neither under conditions of ischemia (6 h) without reperfusion nor ischemia with reperfusion (90 min of ischemia and 18 h of reperfusion).<sup><xref ref-type="bibr" rid="bibr19-1470320311426025">19</xref></sup> Also, pretreatment with ramipril for two weeks before infarction could not decrease infarct size after 60 min of ischemia and 30 min of reperfusion in mice.<sup><xref ref-type="bibr" rid="bibr17-1470320311426025">17</xref></sup> In another study five weeks of treatment with ramipril three weeks after induction of ischemia could not reduce infarct size, but improved cardiac function and less remodeling was observed.<sup><xref ref-type="bibr" rid="bibr29-1470320311426025">29</xref></sup> In the Heart Outcomes Prevention Evaluation (HOPE study) treatment for 4.5 years with ramipril reduced cardiovascular death, non-fatal myocardial infarction and stroke in patients with evidence of vascular disease. But it should be noted that an antihypertensive dose of ramipril (10 mg once daily) was used in this study, and at the end of the study blood pressure in the ramipril group was lower than in the placebo group.<sup><xref ref-type="bibr" rid="bibr20-1470320311426025">20</xref></sup></p>
<p>Our results showed that the protective effect of the ACEi ramiprilat was reversed 10 weeks after administration of the drug. The ACE is a relatively non-specific enzyme and catalyzes not only the conversion of angiotensin I but also the degradation of bradykinin into biologically inactive products. Therefore, ACE-inhibitor treatment may result in accumulation of bradykinin. Bradykinin can stimulate the production of nitric oxide and prostaglandins PGE2 and PGI2 with resultant cardioprotective effects.<sup><xref ref-type="bibr" rid="bibr5-1470320311426025">5</xref></sup> ACE inhibitors block the ACE-mediated production of angiotensin II but non-ACE pathways such as chymase and other enzymes also contribute in angiotensin II production.<sup><xref ref-type="bibr" rid="bibr30-1470320311426025">30</xref></sup> Therefore, in a proportion of patients taking ACE inhibitors over long periods, circulating angiotensin II concentration and/or aldosterone level may return to normal or even elevated levels; the phenomenon has been called ‘angiotensin II reactivation’ and ‘aldosterone escape’, respectively. These phenomena have been shown to abolish the cardioprotective effects of ACEi.<sup><xref ref-type="bibr" rid="bibr31-1470320311426025">31</xref>-<xref ref-type="bibr" rid="bibr33-1470320311426025">33</xref></sup> In another study enalapril, an ACEi, caused a dose- and time-dependent increase in <italic>ACE</italic> gene expression and enzyme concentration in rat tissues, whereas the AT1 blocker losartan produced no change in plasma ACE level.<sup><xref ref-type="bibr" rid="bibr34-1470320311426025">34</xref></sup> Therefore, ACE inhibition may not provide optimal long-term RAS blockade. In addition to the presence of non-ACE pathways for angiotensin II production other explanations that have been suggested for this phenomenon are ACE up-regulation<sup><xref ref-type="bibr" rid="bibr32-1470320311426025">32</xref></sup> reactive hyper-reninemia<sup><xref ref-type="bibr" rid="bibr35-1470320311426025">35</xref></sup> and use of inadequate dose of ACEi,<sup><xref ref-type="bibr" rid="bibr36-1470320311426025">36</xref></sup> so it is possible that increasing the dose of ramiprilat in our study changed the current results. Also, it has been suggested that measurement of the level of different components of the RAS could provide more precise findings in future.</p>
<p>The AT<sub>1</sub> receptor activation is responsible for most of the deleterious effects of angiotensin II in the cardiovascular system including vasoconstriction, aldosterone release, sodium retention, inflammation and increased oxidative stress resulting in cardiac remodeling, whereas angiotensin type 2 (AT<sub>2</sub>) receptor activation leads to vasodilation, control of cell proliferation, promotion of cell differentiation, angiogenesis and protection against ischemia.<sup><xref ref-type="bibr" rid="bibr31-1470320311426025">31</xref>,<xref ref-type="bibr" rid="bibr37-1470320311426025">37</xref></sup> There is also evidence that AT<sub>2</sub> activation stimulates the generation of NO and PGI<sub>2</sub> directly. Therefore, activation of AT<sub>2</sub> appears to antagonize most of the effects of AT<sub>1</sub> activation. As a result, blockade of AT<sub>1</sub> receptors should theoretically be more specific and provide a better suppression for the RAS.<sup><xref ref-type="bibr" rid="bibr31-1470320311426025">31</xref></sup> AT<sub>1</sub>-receptor blockade increases angiotensin II concentration through feedback disinhibition so renders local angiotensin II more accessible to unoccupied AT<sub>2</sub> receptors, causing additional beneficial effects of AT<sub>2</sub> activation.<sup><xref ref-type="bibr" rid="bibr38-1470320311426025">38</xref></sup> AT<sub>1</sub> blockade, like ACEi, limits cardiovascular events but the results from studies on cardiac ischemia reperfusion with losartan are controversial. In most of the experiments, administration of losartan or its active metabolite, EXP3174, immediately prior to ischemia had no significant effect on myocardial infarct size in rat<sup><xref ref-type="bibr" rid="bibr2-1470320311426025">2</xref></sup> or rabbit.<sup><xref ref-type="bibr" rid="bibr3-1470320311426025">3</xref></sup> Explanations for the failure to reduce infarct size may be related to time of application and dosages used. Zhu et al. have reported that losartan has time-dependent cardioprotective effects. In their study myocardial infarct size was unchanged after one day and one week of pretreatment but was significantly reduced by four and 10 weeks of pretreatment with losartan.<sup><xref ref-type="bibr" rid="bibr11-1470320311426025">11</xref>,<xref ref-type="bibr" rid="bibr12-1470320311426025">12</xref></sup> This is consistent with our findings on the potential effect of losartan to decrease the infarct size although we used a much lower dose of losartan and also the effect of losartan on ischemia-induced arrhythmia was investigated in our study.</p>
<p>In summary, it appears that the ACEi ramiprilat and the AT<sub>1</sub> blocker losartan have time-dependent cardioprotective effects against ischemia reperfusion injury at non-hypotensive dose in a rat model of myocardial ischemia reperfusion.</p>
</sec>
</body>
<back>
<ack>
<p>The authors thank Dr Naghdi for providing losartan, Dr Richard Head for providing ramiprilat and Dr Mani for his valuable comments. This work was conducted at the Department of Physiology, Tarbiat Modares University, Tehran, Iran.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This work was supported by a grant from Tarbiat Modares University (150-6150) and Exercise Physiology Research Center, Baqiatallah University of Medical Sciences.</p>
</fn>
<fn fn-type="conflict">
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320311426025">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McMurray</surname><given-names>JJ</given-names></name>
</person-group>. <article-title>ACE inhibitors in cardiovascular disease–unbeatable?</article-title> <source>N Engl J Med</source> <year>2008</year>; <volume>58</volume>: <fpage>1615</fpage>–<lpage>1616</lpage>.</citation>
</ref>
<ref id="bibr2-1470320311426025">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>YH</given-names></name>
<name><surname>Yang</surname><given-names>XP</given-names></name>
<name><surname>Sharov</surname><given-names>VG</given-names></name>
<etal/>
</person-group>. <article-title>Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats</article-title>. <source>Hypertension</source> <year>1996</year>; <volume>27</volume>: <fpage>7</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr3-1470320311426025">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hartman</surname><given-names>JC</given-names></name>
</person-group>. <article-title>The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors</article-title>. <source>Ann Thorac Surg</source> <year>1995</year>; <volume>60</volume>: <fpage>789</fpage>–<lpage>792</lpage>.</citation>
</ref>
<ref id="bibr4-1470320311426025">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sandmann</surname><given-names>S</given-names></name>
<name><surname>Li</surname><given-names>J</given-names></name>
<name><surname>Fritzenkötter</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats</article-title>. <source>Blood Press</source> <year>2006</year>; <volume>15</volume>: <fpage>116</fpage>–<lpage>128</lpage>.</citation>
</ref>
<ref id="bibr5-1470320311426025">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weidenbach</surname><given-names>R</given-names></name>
<name><surname>Schulz</surname><given-names>R</given-names></name>
<name><surname>Gres</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism</article-title>. <source>Br J Pharmacol</source> <year>2000</year>; <volume>131</volume>: <fpage>138</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr6-1470320311426025">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ji</surname><given-names>X</given-names></name>
<name><surname>Tan</surname><given-names>BK</given-names></name>
<name><surname>Zhu</surname><given-names>YC</given-names></name>
<etal/>
</person-group>. <article-title>Comparison of cardioprotective effects using ramipril and DanShen for the treatment of acute myocardial infarction in rats</article-title>. <source>Life Sci</source> <year>2003</year>; <volume>73</volume>: <fpage>1413</fpage>–<lpage>1426</lpage>.</citation>
</ref>
<ref id="bibr7-1470320311426025">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname><given-names>YN</given-names></name>
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
<etal/>
</person-group>. <article-title>(Study on ultrastructure of cardioprotection of ramipril against ischemia/reperfusion injury in diabetic rats)</article-title>. <source>Zhongguo Ying Yong Sheng Li Xue Za Zhi</source> <year>2009</year>; <volume>25</volume>: <fpage>485</fpage>–<lpage>489</lpage>.</citation>
</ref>
<ref id="bibr8-1470320311426025">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laribi</surname><given-names>EM</given-names></name>
<name><surname>Charhbili</surname><given-names>VG</given-names></name>
<name><surname>Gaies</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Cardioprotection and kallikrein–kinin system in acute myocardial ischaemia in mice</article-title>. <source>Clin Exp Pharmacol Physiol</source> <year>2008</year>; <volume>35</volume>: <fpage>489</fpage>–<lpage>493</lpage>.</citation>
</ref>
<ref id="bibr9-1470320311426025">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laribi</surname><given-names>EM</given-names></name>
<name><surname>Gharhbili</surname><given-names>VG</given-names></name>
<name><surname>Pizard</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia</article-title>. <source>J Pharmacol Exp Ther</source> <year>2007</year>; <volume>323</volume>: <fpage>210</fpage>–<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr10-1470320311426025">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huisamen</surname><given-names>B</given-names></name>
<name><surname>Pêrel</surname><given-names>SJ</given-names></name>
<name><surname>Friedrich</surname><given-names>SO</given-names></name>
<etal/>
</person-group>. <article-title>ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance</article-title>. <source>Mol Cell Biochem</source> <year>2011</year>; <volume>349</volume>: <fpage>21</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr11-1470320311426025">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>B</given-names></name>
<name><surname>Sun</surname><given-names>Y</given-names></name>
<name><surname>Sievers</surname><given-names>RE</given-names></name>
<etal/>
</person-group>. <article-title>Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor</article-title>. <source>J Renin Angiotensin Aldosterone Syst</source> <year>2001</year>; <volume>2</volume>: <fpage>129</fpage>–<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr12-1470320311426025">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>B</given-names></name>
<name><surname>Sun</surname><given-names>Y</given-names></name>
<name><surname>Sievers</surname><given-names>RE</given-names></name>
<etal/>
</person-group>. <article-title>Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion</article-title>. <source>J Am Coll Cardiol</source> <year>2000</year> <volume>35</volume>: <fpage>787</fpage>–<lpage>795</lpage>.</citation>
</ref>
<ref id="bibr13-1470320311426025">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>González</surname><given-names>GE</given-names></name>
<name><surname>Seropian</surname><given-names>IM</given-names></name>
<name><surname>Krieger</surname><given-names>ML</given-names></name>
<etal/>
</person-group>. <article-title>Effect of early versus late AT(1) receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <year>2009</year>; <volume>297</volume>: <fpage>H375</fpage>–<lpage>H386</lpage>.</citation>
</ref>
<ref id="bibr14-1470320311426025">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Flynn</surname><given-names>JD</given-names></name>
<name><surname>Akers</surname><given-names>WS</given-names></name>
</person-group>. <article-title>Effects of the angiotensin II subtype 1 receptor antagonist losartan on functional recovery of isolated rat hearts undergoing global myocardial ischemia-reperfusion</article-title>. <source>Pharmacotherapy</source> <year>2003</year>; <volume>23</volume>: <fpage>1401</fpage>–<lpage>1410</lpage>.</citation>
</ref>
<ref id="bibr15-1470320311426025">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ozer</surname><given-names>MK</given-names></name>
<name><surname>Sahna</surname><given-names>E</given-names></name>
<name><surname>Birincioglu</surname></name>
<etal/>
</person-group>. <article-title>Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats</article-title>. <source>Pharmacol Res</source> <year>2002</year>; <volume>45</volume>: <fpage>257</fpage>–<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr16-1470320311426025">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martinez</surname><given-names>L</given-names></name>
<name><surname>Molina</surname><given-names>RV</given-names></name>
</person-group>. <article-title>Early and chronic captopril or losartan therapy reduces infarct size and avoids congestive heart failure after myocardial infarction in rats</article-title>. <source>Arch Med Res</source> <year>2003</year>; <volume>34</volume>: <fpage>357</fpage>–<lpage>361</lpage>.</citation>
</ref>
<ref id="bibr17-1470320311426025">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lange</surname><given-names>SA</given-names></name>
<name><surname>Wolf</surname><given-names>B</given-names></name>
<name><surname>Schober</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-epsilon expression in the mouse heart</article-title>. <source>J Cardiovasc Pharmacol</source> <year>2007</year>; <volume>49</volume>: <fpage>46</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr18-1470320311426025">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matsuhisa</surname><given-names>S</given-names></name>
<name><surname>Otani</surname><given-names>H</given-names></name>
<name><surname>Okazaki</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Angiotensin II type 1 receptor blocker preserves tolerance to ischemia-reperfusion injury in Dahl salt-sensitive rat heart</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <year>2008</year>; <volume>294</volume>: <fpage>H2473</fpage>–<lpage>H2479</lpage>.</citation>
</ref>
<ref id="bibr19-1470320311426025">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Black</surname><given-names>SC</given-names></name>
<name><surname>Driscoll</surname><given-names>EM</given-names></name>
<name><surname>Lucchesi</surname><given-names>BR</given-names></name>
</person-group>. <article-title>Effect of ramiprilat or captopril on myocardial infarct size: assessment in canine models of ischemia alone and ischemia with reperfusion</article-title>. <source>Pharmacology</source> <year>1998</year>; <volume>57</volume>: <fpage>35</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr20-1470320311426025">
<label>20.</label>
<citation citation-type="journal">
<collab>Heart Outcomes Prevention Evaluation (HOPE) Study Investigators</collab>. <source>N Engl J Med</source> <year>2000</year>; <volume>342</volume>: <fpage>145</fpage>–<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr21-1470320311426025">
<label>21.</label>
<citation citation-type="journal">
<collab>ONTARGET Investigators</collab>. <article-title>Telmisartan, ramipril or both in patients at high risk for vascular events</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>358</volume>: <fpage>1547</fpage>–<lpage>1559</lpage>.</citation>
</ref>
<ref id="bibr22-1470320311426025">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hall</surname><given-names>AS</given-names></name>
<name><surname>Winter</surname><given-names>C</given-names></name>
<name><surname>Bogle</surname><given-names>SM</given-names></name>
<etal/>
</person-group>. <article-title>The acute infarction ramipril efficacy (AIRE) study: rationale, design, organization and outcome definitions</article-title>. <source>J Cardiovasc Pharmacol</source> <year>1991</year>; <volume>18</volume>: <fpage>S105</fpage>–<lpage>S109</lpage>.</citation>
</ref>
<ref id="bibr23-1470320311426025">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dickstein</surname><given-names>K</given-names></name>
<name><surname>Kjekshus</surname><given-names>J</given-names></name>
</person-group>. <article-title>Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial</article-title>. <source>Lancet</source> <year>2002</year>; <volume>360</volume>: <fpage>752</fpage>–<lpage>760</lpage>.</citation>
</ref>
<ref id="bibr24-1470320311426025">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baker</surname><given-names>WL</given-names></name>
<name><surname>Coleman</surname><given-names>CI</given-names></name>
<name><surname>Kluger</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease</article-title>. <source>Ann Intern Med</source> <year>2009</year>; <volume>12</volume>: <fpage>861</fpage>–<lpage>871</lpage>.</citation>
</ref>
<ref id="bibr25-1470320311426025">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Siragy</surname><given-names>HM</given-names></name>
</person-group>. <article-title>Comparing angiotensin II receptor blockers on benefits beyond blood pressure</article-title>. <source>Adv Ther</source> <year>2010</year>; <volume>5</volume>: <fpage>257</fpage>–<lpage>284</lpage>.</citation>
</ref>
<ref id="bibr26-1470320311426025">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nickenig</surname><given-names>G</given-names></name>
<name><surname>Ostergren</surname><given-names>J</given-names></name>
<name><surname>Struijker-Boudier</surname><given-names>H</given-names></name>
</person-group>. <article-title>Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers</article-title>. <source>J Renin Angiotensin Aldosterone Syst</source> <year>2006</year>; <volume>7</volume>: <fpage>S1</fpage>–<lpage>S7</lpage>.</citation>
</ref>
<ref id="bibr27-1470320311426025">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Foadoddini</surname><given-names>M</given-names></name>
<name><surname>Esmailidehaj</surname><given-names>M</given-names></name>
<name><surname>Mehrani</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Pretreatment with hyperoxia reduces in vivo infarct size and cell death by apoptosis with an early and delayed phase of protection</article-title>. <source>Eur J Cardiothorac Surg</source> <year>2011</year>; <volume>39</volume>: <fpage>233</fpage>–<lpage>240</lpage>.</citation>
</ref>
<ref id="bibr28-1470320311426025">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walker</surname><given-names>MJ</given-names></name>
<name><surname>Hearse</surname><given-names>DJ</given-names></name>
<name><surname>Campbell</surname><given-names>RW</given-names></name>
</person-group>. <article-title>The Lambeth conventions: guidelines for the study of arrhythmias in ischemia infarction and reperfusion</article-title>. <source>Cardiovasc Res</source> <year>1988</year>; <volume>22</volume>: <fpage>447</fpage>–<lpage>455</lpage>.</citation>
</ref>
<ref id="bibr29-1470320311426025">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname><given-names>J</given-names></name>
<name><surname>Carretero</surname><given-names>OA</given-names></name>
<name><surname>Shesely</surname><given-names>EG</given-names></name>
<etal/>
</person-group>. <article-title>The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice</article-title>. <source>Exp Physiol</source> <year>2009</year>; <volume>94</volume>: <fpage>322</fpage>–<lpage>329</lpage>.</citation>
</ref>
<ref id="bibr30-1470320311426025">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Doggrell</surname><given-names>SA</given-names></name>
<name><surname>Wanstall</surname><given-names>JC</given-names></name>
</person-group>. <article-title>Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors</article-title>. <source>Can J Physiol Pharmacol</source> <year>2005</year>; <volume>83</volume>: <fpage>123</fpage>–<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr31-1470320311426025">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Unger</surname><given-names>T</given-names></name>
</person-group>. <article-title>Targeting cardiovascular protection: the concept of dual renin–angiotensin system control</article-title>. <source>Medscape J Med</source> <year>2008</year>; <volume>10</volume>: <fpage>S4</fpage>.</citation>
</ref>
<ref id="bibr32-1470320311426025">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sharman</surname><given-names>DC</given-names></name>
<name><surname>Morris</surname><given-names>AD</given-names></name>
<name><surname>Struthers</surname><given-names>AD</given-names></name>
</person-group>. <article-title>Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus</article-title>. <source>Diabetologia</source> <year>2007</year>; <volume>50</volume>: <fpage>2061</fpage>–<lpage>2066</lpage>.</citation>
</ref>
<ref id="bibr33-1470320311426025">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>AF</given-names></name>
<name><surname>MacFadyen</surname><given-names>RJ</given-names></name>
<name><surname>Struthers</surname><given-names>AD</given-names></name>
</person-group>. <article-title>Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study</article-title>. <source>Eur J Heart Fail</source> <year>1999</year>; <volume>1</volume>: <fpage>401</fpage>–<lpage>406</lpage>.</citation>
</ref>
<ref id="bibr34-1470320311426025">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Costerousse</surname><given-names>O</given-names></name>
<name><surname>Allegrini</surname><given-names>J</given-names></name>
<name><surname>Clozel</surname><given-names>JP</given-names></name>
<etal/>
</person-group>. <article-title>Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia</article-title>. <source>J Pharmacol Exp Ther</source> <year>1998</year>; <volume>284</volume>: <fpage>1180</fpage>–<lpage>1187</lpage>.</citation>
</ref>
<ref id="bibr35-1470320311426025">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mooser</surname><given-names>V</given-names></name>
<name><surname>Nussberger</surname><given-names>J</given-names></name>
<name><surname>Juillerat</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition</article-title>. <source>J Cardiovasc Pharmacol</source> <year>1990</year>; <volume>15</volume>: <fpage>276</fpage>–<lpage>282</lpage>.</citation>
</ref>
<ref id="bibr36-1470320311426025">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jorde</surname><given-names>UP</given-names></name>
<name><surname>Ennezat</surname><given-names>PV</given-names></name>
<name><surname>Lisker</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure</article-title>. <source>Circulation</source> <year>2000</year>; <volume>101</volume>: <fpage>844</fpage>–<lpage>846</lpage>.</citation>
</ref>
<ref id="bibr37-1470320311426025">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zaman</surname><given-names>MA</given-names></name>
<name><surname>Oparil</surname><given-names>S</given-names></name>
<name><surname>Calhoun</surname><given-names>DA</given-names></name>
</person-group>. <article-title>Drugs targeting the rennin–angiotensin–aldosterone system</article-title>. <source>Nat Rev Drug Discov</source> <year>2002</year>; <volume>1</volume>: <fpage>621</fpage>–<lpage>636</lpage>.</citation>
</ref>
<ref id="bibr38-1470320311426025">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Landmesser</surname><given-names>U</given-names></name>
<name><surname>Drexler</surname><given-names>H</given-names></name>
</person-group>. <article-title>Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide</article-title>. <source>J Hypertens Suppl</source> <year>2006</year>; <volume>24</volume>: <fpage>S39</fpage>–<lpage>S43</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>